X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2787) 2787
Book Review (508) 508
Newsletter (180) 180
Publication (121) 121
Newspaper Article (33) 33
Magazine Article (21) 21
Book Chapter (19) 19
Conference Proceeding (6) 6
Book / eBook (5) 5
Trade Publication Article (3) 3
Reference (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1940) 1940
niacin (1656) 1656
humans (1624) 1624
male (1029) 1029
female (780) 780
niacin - administration & dosage (779) 779
animals (748) 748
middle aged (501) 501
niacin - therapeutic use (497) 497
adult (462) 462
niacin - pharmacology (442) 442
cholesterol (388) 388
old medline (362) 362
pharmacology & pharmacy (353) 353
rats (333) 333
abridged index medicus (327) 327
nicotinic-acid (327) 327
aged (320) 320
drug therapy, combination (285) 285
hypolipidemic agents - therapeutic use (284) 284
atherosclerosis (278) 278
risk factors (268) 268
niacin - adverse effects (264) 264
extended-release niacin (260) 260
research (244) 244
cholesterol, hdl - blood (235) 235
nicotinic acid (233) 233
lipids (230) 230
hypolipidemic agents - administration & dosage (227) 227
cardiac & cardiovascular systems (223) 223
health aspects (213) 213
drug therapy (206) 206
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (205) 205
coronary-heart-disease (203) 203
diet (203) 203
medicine, general & internal (202) 202
delayed-action preparations (201) 201
statins (201) 201
cholesterol, ldl - blood (200) 200
treatment outcome (189) 189
nicotinic acids (185) 185
analysis (179) 179
nutrition & dietetics (175) 175
triglycerides - blood (169) 169
mice (166) 166
prevention (165) 165
metabolism (163) 163
physiological aspects (161) 161
vitamin b (160) 160
hyperlipidemias - drug therapy (158) 158
cardiovascular disease (157) 157
niacin - metabolism (157) 157
care and treatment (156) 156
dose-response relationship, drug (154) 154
biochemistry & molecular biology (153) 153
dosage and administration (153) 153
dyslipidemias - drug therapy (151) 151
niacinamide (144) 144
low density lipoproteins (140) 140
dietary supplements (137) 137
diabetes (134) 134
dyslipidemia (130) 130
hypolipidemic agents - adverse effects (130) 130
endocrinology & metabolism (128) 128
lipoproteins (126) 126
cardiology (125) 125
cardiovascular diseases - prevention & control (125) 125
hypercholesterolemia (124) 124
lipids - blood (124) 124
simvastatin (124) 124
anticholesteremic agents - therapeutic use (122) 122
double-blind method (122) 122
density-lipoprotein cholesterol (121) 121
cardiovascular-disease (119) 119
high-density-lipoprotein (119) 119
cholesterol - blood (118) 118
isoniazid (118) 118
triglycerides (118) 118
adolescent (114) 114
nicotinamide (114) 114
drugs (113) 113
hypolipidemic agents - pharmacology (112) 112
cardiovascular diseases (110) 110
niacin - analogs & derivatives (110) 110
therapy (110) 110
cardiovascular (108) 108
time factors (106) 106
tuberculosis (106) 106
disease (105) 105
coronary heart disease (101) 101
medicine & public health (101) 101
secondary prevention (99) 99
administration, oral (98) 98
hypercholesterolemia - drug therapy (98) 98
safety (97) 97
nicotinic acids - therapeutic use (94) 94
efficacy (93) 93
tryptophan (91) 91
food science & technology (90) 90
medical research (90) 90
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2834) 2834
Russian (57) 57
German (37) 37
Italian (37) 37
French (24) 24
Japanese (18) 18
Spanish (13) 13
Polish (6) 6
Bulgarian (3) 3
Chinese (3) 3
Czech (2) 2
Hungarian (2) 2
Dutch (1) 1
Hebrew (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 4/2009, Volume 101, Issue 7, pp. 507 - 518
Background The General Population Nutrition Intervention Trial was a randomized primary esophageal and gastric cancer prevention trial conducted from 1985 to... 
LUNG-CANCER | DISEASE-SPECIFIC MORTALITY | BETA-CAROTENE SUPPLEMENTS | ONCOLOGY | CARDIOVASCULAR-DISEASE | PRIMARY LIVER-CANCER | RETINOL EFFICACY TRIAL | ALPHA-TOCOPHEROL | RANDOMIZED CONTROLLED-TRIAL | GASTRIC-CARDIA CANCER | BASE-LINE CHARACTERISTICS | alpha-Tocopherol - administration & dosage | Age Factors | Follow-Up Studies | Vitamin A - analogs & derivatives | Humans | Middle Aged | Male | Neoplasms - prevention & control | Malnutrition - complications | Vitamin A - administration & dosage | Niacin - administration & dosage | Aged, 80 and over | Adult | Female | Micronutrients - administration & dosage | Odds Ratio | Risk Factors | Kaplan-Meier Estimate | Neoplasms - mortality | Ascorbic Acid - administration & dosage | beta Carotene - administration & dosage | China - epidemiology | Zinc Oxide - administration & dosage | Confounding Factors (Epidemiology) | Molybdenum - administration & dosage | Antioxidants - administration & dosage | Aged | Dietary Supplements | Selenium - administration & dosage | Vitamins - administration & dosage | Riboflavin - administration & dosage | Complications and side effects | Diet therapy | Mortality | Dietary supplements | Research | Health aspects | Risk factors | Vitamins | Cancer | Nutrition research | Dietary minerals | Clinical trials | Oncology | Clinical outcomes | Index Medicus
Journal Article
Journal of Nutrition, ISSN 0022-3166, 2016, Volume 146, Issue 9, pp. 1866S - 1873S
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 203 - 212
Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant... 
NICOTINIC-ACID | LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | PLACEBO-CONTROLLED TRIAL | NIACIN/LAROPIPRANT | DYSLIPIDEMIA | Follow-Up Studies | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Indoles - administration & dosage | Infection - chemically induced | Niacin - administration & dosage | Treatment Failure | Musculoskeletal Diseases - chemically induced | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Double-Blind Method | Risk Factors | Indoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus - chemically induced | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Drug Combinations | Dose-response relationship (Biochemistry) | Laropiprant | Blood circulation disorders | Care and treatment | Dosage and administration | Niacin | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Heart attacks | Risk groups | Diabetes mellitus | Cardiovascular disease | Low density lipoprotein | Cholesterol | Musculoskeletal system | Vascular diseases | Arteriosclerosis | Vitamin B | Skin | Lipoproteins (high density) | Drug dosages | Statins | Index Medicus | Abridged Index Medicus
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2013, Volume 34, Issue 17, pp. 1279 - 1291
Journal Article
Journal of Dairy Science, ISSN 0022-0302, 08/2016, Volume 99, Issue 8, pp. 6229 - 6236
Journal Article
Cardiovascular Therapeutics, ISSN 1755-5914, 08/2014, Volume 32, Issue 4, pp. 139 - 146
Introduction: Oxidative stress plays an important role in atherosclerosis. Both F2-isoprostane (8-iso-PGF2a) and oxidized low-density lipoprotein (ox-LDL) have... 
nicotinic acid/laropiprant | LDL | oxidized | fenofibrate | F2‐Isoprostanes | rosuvastatin | oxidative stress | mixed dyslipidemia | Fenofibrate | Oxidative stress | Nicotinic acid/laropiprant | Oxidized LDL | F2-Isoprostanes | Rosuvastatin | Mixed dyslipidemia | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | ATHEROSCLEROSIS | RISK | APOLIPOPROTEINS | COMBINATION | HIGH-DENSITY-LIPOPROTEIN | THERAPY | PHARMACOLOGY & PHARMACY | oxidized LDL | CIRCULATING OXIDIZED LDL | AUTOANTIBODY | HYPOLIPIDEMIC TREATMENT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dinoprost - blood | Prospective Studies | Humans | Middle Aged | Apolipoprotein B-100 - blood | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Fenofibrate - adverse effects | Greece | Niacin - administration & dosage | Dyslipidemias - blood | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Niacin - adverse effects | Female | Dinoprost - analogs & derivatives | Uric Acid - blood | Drug Therapy, Combination | Dyslipidemias - diagnosis | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Fenofibrate - administration & dosage | Rosuvastatin Calcium | Treatment Outcome | Biomarkers - blood | Atorvastatin Calcium | Bilirubin - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Hypolipidemic Agents - administration & dosage | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Oxidative Stress - drug effects | Lipoproteins, LDL - blood | Sulfonamides - administration & dosage | Care and treatment | Low density lipoproteins | Analysis | Simvastatin | Atherosclerosis | Fibric acids | Cardiovascular agents | Index Medicus
Journal Article